BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the full year and fourth quarter ended December 31, 2023.
“We made excellent pipeline and corporate progress during 2023 and early 2024, highlighted by the encouraging initial clinical results reported from our MRT-2359 Phase 1/2 study in October. We also continued to advance our VAV1-directed MGD, MRT-6160, for autoimmune diseases toward the clinic, and we progressed MRT-8102, a NEK7-directed MGD targeting IL-1b and the NLRP3 inflammasome, into IND-enabling studies. We are excited about the broad potential of MRT-2359 in MYC-driven cancers, as well as the opportunity that exists with both the VAV1 and NEK7 programs to address pathways of emerging clinical significance in systemic and neurological autoimmune and inflammatory diseases,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. “In addition, we entered into a strategic research collaboration with Roche to enable broader application of our technology. All combined, the terrific progress we made in the last 12 month highlights the uniqueness and differentiation of our approach and the strength of our ML/AI-driven QuEEN™ discovery engine. We look forward to building on that success with continued pipeline execution across multiple programs targeting substantial patient populations, and our anticipated cash runway into the first half of 2026 positions us well to do so.”
2023 AND RECENT HIGHLIGHTS
ANTICIPATED UPCOMING MILESTONES
UPCOMING PRESENTATIONS
FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $27.1 million, compared to $24.9 million for the fourth quarter of 2022, and $111.3 million for the year ended December 31, 2023, compared to $85.1 million for the year ended December 31, 2022. These increases were driven by the successful achievement of key milestones in our R&D organization, including the continuation of the MRT-2359 clinical study, the progression and growth of our preclinical pipeline, the preparation of MRT-6160 to enter the clinic, and the continued development of the Company’s QuEEN™ discovery engine, and reflect increased personnel expense and external R&D costs including laboratory-related expenses to achieve these milestones. Non-cash stock-based compensation constituted $2.2 million of R&D expenses for Q4 2023, compared to $1.8 million in the same period in 2022, and $8.9 million and $5.6 million for the years ended December 31, 2023 and 2022, respectively.
General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $7.7 million compared to $7.6 million for the fourth quarter of 2022, and $32.0 million for the year ended December 31, 2023, compared to $27.3 million for the year ended December 31, 2022. The increase in G&A expenses was a result of increased headcount and expenses in support of the Company’s growth and operations. G&A expenses included non-cash stock-based compensation of $1.8 million for the fourth quarter of 2023, compared to $1.6 million for the same period in 2022, and $7.7 million and $6.1 million for the years ended December 31, 2023 and 2022, respectively.
Net Loss: Net loss for the fourth quarter of 2023 was $33.3 million, compared to $30.8 million for the fourth quarter of 2022, and $135.4 million for the year ended December 31, 2023, compared to $108.5 million for the year ended December 31, 2022.
Cash Position and Financial Guidance: Cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2023, were $237.0 million, compared to cash, cash equivalents, restricted cash, and marketable securities of $183.0 million as of September 30, 2023. The increase of $54 million was primarily related to the proceeds from the Roche collaboration and registered direct offering in Q4 2023.
The Company expects its cash and cash equivalents, including proceeds from the Roche collaboration, to be sufficient to fund planned operations and capital expenditures into the first half of 2026.
About MRT-2359
MRT-2359 is a potent, highly selective and orally bioavailable investigational molecular glue degrader (MGD) that induces the interaction between the E3 ubiquitin ligase component cereblon and the translation termination factor GSPT1, leading to the targeted degradation of GSPT1 protein. The MYC transcription factors (c‑MYC, L-MYC and N-MYC) are well-established drivers of human cancers that maintain high levels of protein translation, which is critical for uncontrolled cell proliferation and tumor growth. Preclinical studies have shown this addiction to MYC-induced protein translation creates a dependency on GSPT1. By inducing degradation of GSPT1, MRT-2359 is designed to exploit this vulnerability, disrupting the protein synthesis machinery, leading to anti-tumor activity in MYC-driven tumors.
About MRT-6160
MRT-6160 is a potent, highly selective, and orally bioavailable investigational molecular glue degrader of VAV1, which in our in vitro studies has shown deep degradation of its target with no detectable effects on other proteins. VAV1, a Rho-family guanine nucleotide exchange factor, is a key signaling protein downstream of both the T- and B-cell receptors. VAV1 expression is restricted to blood and immune cells, including T and B cells. Preclinical studies have shown that targeted degradation of VAV1 protein via an MGD modulates both T- and B-cell receptor-mediated activity. This modulation is evident both in vitro and in vivo, demonstrated by a significant decrease in cytokine secretion, proteins vital for maintaining autoimmune diseases. Moreover, VAV1-directed MGDs have shown promising activity in preclinical models of autoimmune diseases and thus have the potential to provide therapeutic benefits in multiple systemic and neurological autoimmune indications, such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and dermatological disorders. Preclinical studies demonstrate MRT-6160 inhibits disease progression in in vivo autoimmunity models.
About MRT-8102
\MRT-8102 is a potent, highly selective, and orally bioavailable investigational molecular glue degrader (MGD) that targets NEK7 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. NEK7 has been shown to be required for NLRP3 inflammasome assembly, activation and IL-1b release both in vitro and in vivo. Aberrant NLRP3 inflammasome activation and the subsequent release of active IL-1b and interleukin-18 (IL-18) has been implicated in multiple inflammatory disorders, including gout, cardiovascular disease, neurologic disorders including Parkinson’s disease and Alzheimer’s disease, ocular disease, diabetes, obesity, and liver disease. In a non-human primate model, MRT-8102 potently, selectively, and durably degrades NEK7 and results in near-complete reductions of IL-1b models following ex vivo stimulation of whole blood. MRT-8102 has shown a favorable profile in non-GLP toxicology studies.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained herein include, but are not limited to, statements about our product development activities, our ability to grow our product pipeline, our ongoing clinical development of our GSPT1 degrader referred to as MRT-2359, including our expectations for the nature, significance, and timing for our disclosure of any initial data from our Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors, timing for our identification and any disclosure of a recommended phase 2 dose for MRT-2359, statements the Company’s QuEENTM discovery engine and the Company’s view of its potential to identify degradable protein targets and rationally design MGDs with unprecedented selectivity, statements about our collaboration with Roche, statements about the advancement and timeline of our preclinical and clinical programs, pipeline and the various products therein, including the ongoing development of our VAV1-directed degrader, referred to as MRT-6160, the planned submission of an IND to the FDA for MRT-6160 in Q2 2024, and our expectations of timing for commencing any Phase 1 single ascending dose / multiple ascending dose (SAD/MAD) study initiation in healthy volunteers, our expectations regarding the potential clinical benefit for our programs and our expectations of timings for the program, the ongoing development of our NEK7-directed degrader, referred to as MRT-8102, the planned submission of an IND to the FDA for MRT-8102 in the first quarter of 2025, and our expectations of timing for clinical advancement for MRT-8102, statements around the identification and the timing of a development candidate for CDK2 and other programs, statements around the advancement and application of our platform, and statements concerning our expectations regarding our ability to nominate and the timing of our nominations of additional targets, product candidates, and development candidates, as well as our expectations of success for our programs and the strength of our financial position, our use of capital, expenses and other financial results in the future, availability of funding for existing programs, ability to fund operations into the first half of 2026, among others. By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on March 14, 2024, and any subsequent filings, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law. Certain information contained in these materials and any statements made orally during any presentation of these materials that relate to the materials or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of these materials, we have not independently verified, and make no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in these materials relating to or based on such internal estimates and research.
| Consolidated Balance Sheets | ||||||||||||||||||||||||||||
| (in thousands, except share amounts) | ||||||||||||||||||||||||||||
| December 31, | ||||||||||||||||||||||||||||
| 2023 | 2022 | |||||||||||||||||||||||||||
| Assets | ||||||||||||||||||||||||||||
| Current assets: | ||||||||||||||||||||||||||||
| Cash and cash equivalents | $ | 128,101 | $ | 54,912 | ||||||||||||||||||||||||
| Marketable securities | 104,312 | 207,914 | ||||||||||||||||||||||||||
| Other receivables | 505 | 7,656 | ||||||||||||||||||||||||||
| Prepaid expenses and other current assets | 3,294 | 4,444 | ||||||||||||||||||||||||||
| Current restricted cash | — | 960 | ||||||||||||||||||||||||||
| Total current assets | 236,212 | 275,886 | ||||||||||||||||||||||||||
| Property and equipment, net | 33,803 | 27,075 | ||||||||||||||||||||||||||
| Operating lease right-of-use assets | 28,808 | 34,832 | ||||||||||||||||||||||||||
| Restricted cash, net of current | 4,580 | 4,318 | ||||||||||||||||||||||||||
| Other long-term assets | 352 | 278 | ||||||||||||||||||||||||||
| Total assets | $ | 303,755 | $ | 342,389 | ||||||||||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||||||||||
| Accounts payable | $ | 11,152 | $ | 7,862 | ||||||||||||||||||||||||
| Accrued expenses and other current liabilities | 14,600 | 14,580 | ||||||||||||||||||||||||||
| Current deferred revenue | 17,678 | — | ||||||||||||||||||||||||||
| Current portion of operating lease liability | 3,162 | 3,127 | ||||||||||||||||||||||||||
| Total current liabilities | 46,592 | 25,569 | ||||||||||||||||||||||||||
| Deferred revenue, net of current | 32,323 | — | ||||||||||||||||||||||||||
| Defined benefit plan liability | 2,713 | 1,533 | ||||||||||||||||||||||||||
| Operating lease liability | 42,877 | 43,874 | ||||||||||||||||||||||||||
| Total liabilities | 124,505 | 70,976 | ||||||||||||||||||||||||||
| Commitments and contingencies | ||||||||||||||||||||||||||||
| Stockholders’ equity | ||||||||||||||||||||||||||||
| Common stock, $0.0001 par value; 500,000,000 shares authorized, 50,154,929 shares issued and 50,140,233 shares outstanding as of December 31, 2023; and 500,000,000 shares authorized, 49,445,802 shares issued and 49,323,531 shares outstanding as of December 31, 2022 | 5 | 5 | ||||||||||||||||||||||||||
| Additional paid-in capital | 547,857 | 503,696 | ||||||||||||||||||||||||||
| Accumulated other comprehensive loss | (2,724 | ) | (1,752 | ) | ||||||||||||||||||||||||
| Accumulated deficit | (365,888 | ) | (230,536 | ) | ||||||||||||||||||||||||
| Total stockholders’ equity | 179,250 | 271,413 | ||||||||||||||||||||||||||
| Total liabilities and stockholders’ equity | $ | 303,755 | $ | 342,389 | ||||||||||||||||||||||||
| Consolidated Statements of Operations and Comprehensive Income (Loss) | ||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||
| Three months ended December 31, | Year ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 27,135 | $ | 24,868 | $ | 111,272 | $ | 85,061 | ||||||||
| General and administrative | 7,728 | 7,621 | 32,039 | 27,323 | ||||||||||||
| Total operating expenses | 34,863 | 32,489 | 143,311 | 112,384 | ||||||||||||
| Loss from operations | (34,863 | ) | (32,489 | ) | (143,311 | ) | (112,384 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income, net | 2,368 | 1,990 | 9,334 | 3,764 | ||||||||||||
| Foreign currency exchange gain (loss), net | (779 | ) | (283 | ) | (930 | ) | 10 | |||||||||
| Gain on disposal of fixed assets | — | — | 24 | 109 | ||||||||||||
| Loss on sale of marketable securities | — | — | (131 | ) | — | |||||||||||
| Total other income | 1,589 | 1,707 | 8,297 | 3,883 | ||||||||||||
| Net loss before income taxes | $ | (33,274 | ) | $ | (30,782 | ) | $ | (135,014 | ) | $ | (108,501 | ) | ||||
| Provision for income taxes | 22 | — | (338 | ) | — | |||||||||||
| Net loss | $ | (33,252 | ) | $ | (30,782 | ) | $ | (135,352 | ) | $ | (108,501 | ) | ||||
| Net loss per share attributable to common stockholders—basic and diluted | $ | (0.58 | ) | $ | (0.63 | ) | $ | (2.63 | ) | $ | (2.30 | ) | ||||
| Weighted-average number of shares outstanding used in computing net loss per common share—basic and diluted | 56,927,647 | 48,893,160 | 51,396,961 | 47,227,370 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (33,252 | ) | $ | (30,782 | ) | $ | (135,352 | ) | $ | (108,501 | ) | ||||
| Provision for pension benefit obligation | (1,411 | ) | 619 | (1,369 | ) | 718 | ||||||||||
| Unrealized gain (loss) on available-for-sale securities | 142 | 231 | 397 | (449 | ) | |||||||||||
| Comprehensive loss | $ | (34,521 | ) | $ | (29,932 | ) | $ | (136,324 | ) | $ | (108,232 | ) | ||||
Investors
Andrew Funderburk
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Cory Tromblee, Scient PR
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$10.05 |
| Daily Change: | 0.94 10.32 |
| Daily Volume: | 883,716 |
| Market Cap: | US$616.770M |
November 07, 2024 October 28, 2024 August 19, 2024 August 08, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
